RT Journal Article
SR Electronic
T1 Characterizing the genetic architecture of Parkinson’s disease in Latinos
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20227124
DO 10.1101/2020.11.09.20227124
A1 Loesch, Douglas
A1 Horimoto, Andrea R. V. R.
A1 Heilbron, Karl
A1 Sarihan, Elif Irem
A1 Inca-Martinez, Miguel
A1 Mason, Emily
A1 Cornejo-Olivas, Mario
A1 Torres, Luis
A1 Mazzetti, Pilar
A1 Cosentino, Carlos
A1 Sarapura-Castro, Elison
A1 Rivera-Valdivia, Andrea
A1 Medina, Angel C.
A1 Dieguez, Elena
A1 Raggio, Victor
A1 Lescano, Andres
A1 Tumas, Vitor
A1 Borges, Vanderci
A1 Ferraz, Henrique B.
A1 Rieder, Carlos R.
A1 Schumacher-Schuh, Artur
A1 Santos-Lobato, Bruno L.
A1 Velez-Pardo, Carlos
A1 Jimenez-Del-Rio, Marlene
A1 Lopera, Francisco
A1 Moreno, Sonia
A1 Chana-Cuevas, Pedro
A1 Fernandez, William
A1 Arboleda, Gonzalo
A1 Arboleda, Humberto
A1 Arboleda-Bustos, Carlos E.
A1 Yearout, Dora
A1 Zabetian, Cyrus P.
A1 ,
A1 Cannon, Paul
A1 Thornton, Timothy A.
A1 O’Connor, Timothy D.
A1 Mata, Ignacio F.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20227124.abstract
AB To date, over 90 Parkinson’s disease (PD) risk variants have been reported from genome-wide association studies (GWAS). However, these GWAS efforts have been limited to individuals of European and East Asian ancestry. We performed the first GWAS of Latino PD patients from South America, comparing 807 cases against 690 controls followed by association testing of suggestive loci in a replication cohort of 1,234 cases and 439,522 controls. We demonstrated that SNCA plays a significant role in PD etiology in a Latino cohort and identified a suggestive locus near NRROS on chromosome 3 that appeared to be driven by Peruvian subjects. We also characterized the overlap of PD genetic architecture between Europeans and Latinos with a replication of significant variants identified by Nalls et al. in their 2019 GWAS1, finding 80% concordance in direction of effect. We then leveraged the population history of Latinos via admixture mapping, identifying a significant locus on chromosome 14 in a joint test of ancestries, driven by the Native American ancestral background, and a significant locus on chromosome 6 in our test of African ancestry, containing the genes STXBP6 and RPS6KA2, respectively. Ultimately, our work reflects the most comprehensive characterization of PD genetic architecture in Latinos to date.Competing Interest StatementKarl Heilbron and Paul Cannon are current or former employees of 23andMe, Inc. and may hold stock or stock options. All other authors declare no conflicts of interest.Funding StatementThis work was supported by a Stanley Fahn Junior Faculty Award and an International Research Grants Program award from the Parkinson's Foundation, by a research grant from the American Parkinson's Disease Association, and with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System. This project was partially supported by The Committee for Development and Research (Comite para el desarrollo y la investigación-CODI)-Universidad de Antioquia grant #2020-31455 to MJ-Del-Rio and CV-P. DL was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL007698. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by VA Puget Sound IRB, with the project name "LARGE-PD: Latin American Research Consortium of the Genetics of Parkinson's Disease", RDIS number: 0010, MIRB number: 00087. Currently, the study is under Cleveland Clinic IRB: 19-340. For the replication study, 23andMe protocols were reviewed and approved by Ethical & Independent Review Services, a private institutional review board (http://www.eandireview.com). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full LARGE-PD GWAS summary statistics are available upon request. Summary statistics for the 23andMe replication dataset are given in the manuscript.